Phibro Animal Health Revenue Growth Rates (PAHC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Phibro Animal Health Corporation  (NASDAQ: PAHC)
 

PAHC's Revenue Growth by Quarter and Year

Phibro Animal Health's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PAHC/growth
https://api.csimarket.com/api/v1/companies/PAHC/fundamentals
https://api.csimarket.com/api/v1/companies/PAHC/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PAHC Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 386.77
FY 386.77

PAHCs Annual Revenue
Phibro Animal Health's Revenue in the fiscal year 2026 $ 1,518.09 millions
Phibro Animal Health's Revenue in the fiscal year 2025 $ 1,295.94 millions
Phibro Animal Health's Revenue in the fiscal year 2024 $ 1,017.09 millions
Phibro Animal Health's Revenue in the fiscal year 2023 $ 977.24 millions
Phibro Animal Health's Revenue in the fiscal year 2022 $ 942.26 millions




PAHC Revenue first quarter 2026 Y/Y Growth Comment
Phibro Animal Health Corporation reported Revenue growth of 6.32% year on year in the first quarter 2026, to $ 386.77 millions, this is lower than Phibro Animal Health Corporation's recent average Revenue growth of 7.12%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 121 other companies have achieved higher Revenue growth. While Phibro Animal Health Corporation' s Revenue increase of 6.32% ranks overall at the positon no. 2316 in the first quarter 2026.


PAHC Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 6.32 %
FY   -

Financial Statements
Phibro Animal Health's first quarter 2026 Revenue $ 386.77 millions PAHC's Income Statement
Phibro Animal Health's first quarter 2025 Revenue $ 363.78 millions Quarterly PAHC's Income Statement


PAHC Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September -2.51 %
FY (Year on Year)   -


Back to PAHC Growth rate Comparisons >> Back to PAHC Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #122
Healthcare Sector #339
Overall #2316

Revenue Y/Y Growth Statistics
High Average Low
40.19 % 7.12 % -8.83 %
(Sep 30 2025)   (Jun 30 2020)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #122
Healthcare Sector #339
Overall #2316
Revenue Y/Y Growth Statistics
High Average Low
40.19 % 7.12 % -8.83 %
(Sep 30 2025)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Phibro Animal Health's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
19.03 % 1.79 % -11.79 %
(Dec 31 2024)  


PAHC's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Phibro Animal Health Corporation disclosed fall in Revenue from the fourth quarter by -2.51% to $ 386.77 millions, from $ 396.75 millions achived in the previous reporting period.

But that's not important problem, as Phibro Animal Health's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 72 other companies have achieved higher Revenue quarter on quarter growth. While Phibro Animal Health's Revenue growth quarter on quarter, overall rank is 1243.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #180
Overall #1243
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #180
Overall #1243
Revenue Q/Q Growth Statistics
High Average Low
19.03 % 1.79 % -11.79 %
(Dec 31 2024)  


PAHC's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Phibro Animal Health Corporation disclosed fall in Revenue from the fourth quarter by -2.51% to $ 386.77 millions, from $ 396.75 millions achived in the previous reporting period.

But that's not important problem, as Phibro Animal Health's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 72 other companies have achieved higher Revenue quarter on quarter growth. While Phibro Animal Health's Revenue growth quarter on quarter, overall rank is 1243.


Phibro Animal Health's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1,516.86
Y / Y Revenue Growth (TTM) 17.05 %
Year on Year Revenue Growth Overall Ranking # 603
Seqeuential Revenue Change (TTM) 1.12 %
Seq. Revenue Growth (TTM) Overall Ranking # 1599


Cumulative Revenue growth Comment
Assuming the Phibro Animal Health's fiscal year would have ended in Jun 30 2026, Phibro Animal Health would have reprted above average annual Revenue increase of 17.05% year on year, of $ 1,517 millions.
This marks a slow-down of the companys growth trends and from the 26.05% improvement in Mar 31 2026.

In the Healthcare sector 129 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 603, from total ranking in previous quarter at 803.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 88
Healthcare Sector # 130
Overall # 603

Revenue TTM Y/Y Growth Statistics
High Average Low
33.88 %
 6.97 %
-3.34 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 88
Sector # 260
S&P 500 # 1599
Cumulative Revenue growth Comment
Assuming the Phibro Animal Health's fiscal year would have ended in Jun 30 2026, Phibro Animal Health would have reprted above average annual Revenue increase of 17.05% year on year, of $ 1,517 millions.
This marks a slow-down of the companys growth trends and from the 26.05% improvement in Mar 31 2026.

In the Healthcare sector 129 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 603, from total ranking in previous quarter at 803.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 88
Healthcare Sector # 130
Overall # 603

Revenue TTM Y/Y Growth Statistics
High Average Low
33.88 %
6.97 %
-3.34 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 88
Sector # 260
S&P 500 # 1599




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PAHC's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue improvement for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Pro dex Inc 10.96%$ 10.955 millions
Nrc Health10.95%$ 10.954 millions
Anika Therapeutics Inc 10.91%$ 10.912 millions
Harvard Bioscience Inc 10.86%$ 10.864 millions
Repligen Corp10.86%$ 10.863 millions
Warby Parker Inc 10.77%$ 10.767 millions
Cerus Corporation10.69%$ 10.690 millions
Biogen Inc 10.63%$ 10.628 millions
Chemed Corporation10.57%$ 10.568 millions
Edwards Lifesciences Corporation10.47%$ 10.471 millions
Biodesix Inc 10.44%$ 10.442 millions
Medline Inc 10.41%$ 10.415 millions
Jazz Pharmaceuticals Plc10.38%$ 10.380 millions
Abbvie Inc 10.32%$ 10.319 millions
Livanova Plc10.17%$ 10.170 millions
Kura Oncology Inc 10.07%$ 10.067 millions
Amneal Pharmaceuticals Inc 10.04%$ 10.040 millions
Quest Diagnostics Inc9.98%$ 9.979 millions
Idexx Laboratories Inc9.95%$ 9.950 millions
Bausch Health Companies Inc 9.70%$ 9.698 millions
Marpai Inc9.59%$ 9.586 millions
Haemonetics Corporation9.49%$ 9.492 millions
Progyny Inc 9.08%$ 9.084 millions
Ironwood Pharmaceuticals inc 9.00%$ 8.996 millions
Encompass Health Corporation8.93%$ 8.934 millions
West Pharmaceutical Services Inc 8.73%$ 8.728 millions
Resmed Inc 8.67%$ 8.667 millions
Carlisle Companies Incorporated8.65%$ 8.649 millions
Concentra Group Holdings Parent Inc 8.61%$ 8.611 millions
Merit Medical Systems Inc8.56%$ 8.563 millions


About Phibro Animal Health Revenue Growth Rates (PAHC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Phibro Animal Health Corp (CIK 1069899).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-122692
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Phibro Animal Health Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.